When managing patients with XLH
CRYSVITA (burosumab injection) is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
XLH is a genetic disease affecting children into adulthood, characterized by hypophosphatemia due to increased fibroblast growth factor 23 (FGF23) levels.1,3-5
Not actual patients.
FGF23=fibroblast growth factor 23; XLH=X-linked hypophosphatemia.
† Comparative clinical significance has not been established.
References: 1. CRYSVITA (burosumab injection) Product
Monograph. Kyowa Kirin Inc. March 15, 2023. 2. Data on file.
First and only claim. Kyowa Kirin Inc. 3. Glorieux FH, et
al. Potential influences on optimizing long-term musculoskeletal health in children
and adolescents with X-linked hypophosphatemia (XLH). Orphanet J Rare Dis.
2022;17(1):30.
4. Haffner D, et al. Clinical
practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat
Rev Nephrol. 2019;15(7):435-455. 5. Dahir K, et al.
X-linked hypophosphatemia: A new era in management. J Endocr Soc.
2020;4(12):bvaa151.
